SCHEMBL25548976

SCHEMBL25548976

CC(C)([C@H](NC(=O)c1ccc2cc(F)ccc2c1OCc1ccc(S(F)(F)(F)(F)F)cc1)C(=O)O)S(C)(=O)=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 2/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.33
▸ ITGB3 P05106 1/20 0.31
▸ ITGB1 P05556 1/20 0.31
▸ ITGAV P06756 1/20 0.31
▸ ITGA5 P08648 1/20 0.31
▸ KCNQ3 O43525 1/20 0.31
▸ KCNQ2 O43526 1/20 0.31
▸ KCNQ5 Q9NR82 1/20 0.31
▸ ADAMTS4 O75173 2/20 0.31
▸ CNR1 P21554 2/20 0.30
▸ CNR2 P34972 2/20 0.30
▸ ABHD12 Q8N2K0 1/20 0.30
▸ MAOB P27338 2/20 0.30
▸ MAOA P21397 1/20 0.30
▸ MME P08473 1/20 0.30
▸ ACE P12821 1/20 0.30
▸ CPA1 P15085 1/20 0.30
▸ ACE2 Q9BYF1 1/20 0.30
▸ GPR34 Q9UPC5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25549762 0.91 CXCR2 (0.38) CXCR2FFAR4ITGB3ITGB1ITGAV
SCHEMBL25548714 0.91 CXCR2 (0.38) CXCR2FFAR4ITGB3ITGB1ITGAV
SCHEMBL25549143 0.89 CXCR2 (0.47) CXCR2ADAMTS4MMEACECPA1
SCHEMBL25549148 0.89 CXCR2 (0.46) CXCR2KCNQ3KCNQ2KCNQ5MAOA
SCHEMBL25548983 0.88 PTGDR2 (0.37) CXCR2FFAR4MAOBMAOA
SCHEMBL25549139 0.87 CXCR2 (0.40) CXCR2FFAR4
SCHEMBL25548880 0.84 CXCR2 (0.37) CXCR2FFAR4ITGB3ITGB1ITGAV
SCHEMBL25549083 0.82 PYGL (0.47) CXCR2FFAR4ADAMTS4
SCHEMBL25555270 0.82 PYGL (0.47) CXCR2FFAR4ADAMTS4
SCHEMBL25560540 0.80 CXCR2 (0.38) CXCR2FFAR4ADAMTS4CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885FFAR4 2302/4885ITGB3 3195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback